Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Exagen Q3 Adj. EPS $(0.19) Misses $(0.16) Estimate, Sales $17.244M Beat $16.895M Estimate

Author: Benzinga Newsdesk | November 04, 2025 09:38am
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 20.25 percent. This is a 32.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $17.244 million which beat the analyst consensus estimate of $16.895 million by 2.07 percent. This is a 37.87 percent increase over sales of $12.507 million the same period last year.

Posted In: XGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist